Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.

Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, Collett MS, Rhodes G, Tohan S, Huggins JW, Baker RO, Kern ER, Keith KA, Dai D, Yang G, Hruby D, Jordan R.

J Med Chem. 2007 Apr 5;50(7):1442-4. Epub 2007 Mar 3.

2.

Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, De Clercq E, Andrei G.

Antivir Ther. 2007;12(8):1205-16.

PMID:
18240860
3.

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.

J Virol. 2005 Oct;79(20):13139-49.

4.

Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.

Narjes F, Crescenzi B, Ferrara M, Habermann J, Colarusso S, Ferreira Mdel R, Stansfield I, Mackay AC, Conte I, Ercolani C, Zaramella S, Palumbi MC, Meuleman P, Leroux-Roels G, Giuliano C, Fiore F, Di Marco S, Baiocco P, Koch U, Migliaccio G, Altamura S, Laufer R, De Francesco R, Rowley M.

J Med Chem. 2011 Jan 13;54(1):289-301. doi: 10.1021/jm1013105. Epub 2010 Dec 8.

PMID:
21141896
5.

Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.

Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, Frimm A, Corrado ML, Strome PG, Hruby DE.

Antimicrob Agents Chemother. 2008 May;52(5):1721-7. doi: 10.1128/AAC.01303-07. Epub 2008 Mar 3.

6.

Polycyclic N-benzamido imides with potent activity against vaccinia virus.

Torres E, Duque MD, Camps P, Naesens L, Calvet T, Font-Bardia M, Vázquez S.

ChemMedChem. 2010 Dec 3;5(12):2072-8. doi: 10.1002/cmdc.201000306.

PMID:
20967819
7.

Molecule of the month. Tecovirimat.

[No authors listed]

Drug News Perspect. 2008 Nov;21(9):517. No abstract available.

PMID:
19180269
8.

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Tedesco R, Shaw AN, Bambal R, Chai D, Concha NO, Darcy MG, Dhanak D, Fitch DM, Gates A, Gerhardt WG, Halegoua DL, Han C, Hofmann GA, Johnston VK, Kaura AC, Liu N, Keenan RM, Lin-Goerke J, Sarisky RT, Wiggall KJ, Zimmerman MN, Duffy KJ.

J Med Chem. 2006 Feb 9;49(3):971-83.

PMID:
16451063
9.

Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.

Santos-Fernandes É, Beltrame CO, Byrd CM, Cardwell KB, Schnellrath LC, Medaglia ML, Hruby DE, Jordan R, Damaso CR.

Antiviral Res. 2013 Mar;97(3):301-11. doi: 10.1016/j.antiviral.2012.11.010. Epub 2012 Dec 17.

10.

A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity.

Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3224-8. Epub 2006 Apr 5.

PMID:
16603351
11.

Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.

Onda K, Shiraki R, Ogiyama T, Yokoyama K, Momose K, Katayama N, Orita M, Yamaguchi T, Furutani M, Hamada N, Takeuchi M, Okada M, Ohta M, Tsukamoto S.

Bioorg Med Chem. 2008 Dec 1;16(23):10001-12. doi: 10.1016/j.bmc.2008.10.021. Epub 2008 Oct 12.

PMID:
18952447
12.

Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.

Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE.

Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.

13.

Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.

Li H, Tatlock J, Linton A, Gonzalez J, Jewell T, Patel L, Ludlum S, Drowns M, Rahavendran SV, Skor H, Hunter R, Shi ST, Herlihy KJ, Parge H, Hickey M, Yu X, Chau F, Nonomiya J, Lewis C.

J Med Chem. 2009 Mar 12;52(5):1255-8. doi: 10.1021/jm8014537.

PMID:
19209845
14.

Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3582-6. doi: 10.1128/AAC.06090-11. Epub 2012 Apr 23.

15.

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

Chen Y, Amantana A, Tyavanagimatt SR, Zima D, Yan XS, Kasi G, Weeks M, Stone MA, Weimers WC, Samuel P, Tan Y, Jones KF, Lee DR, Kickner SS, Saville BM, Lauzon M, McIntyre A, Honeychurch KM, Jordan R, Hruby DE, Leeds JM.

PLoS One. 2011;6(8):e23237. doi: 10.1371/journal.pone.0023237. Epub 2011 Aug 15.

16.

Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.

Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.

PMID:
12941314
17.

Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, Bolken TC, Leeds JM, Hruby DE.

PLoS One. 2013 Apr 18;8(4):e61514. doi: 10.1371/journal.pone.0061514. Print 2013.

18.

Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.

Sun D, Wang Z, Caille S, DeGraffenreid M, Gonzalez-Lopez de Turiso F, Hungate R, Jaen JC, Jiang B, Julian LD, Kelly R, McMinn DL, Kaizerman J, Rew Y, Sudom A, Tu H, Ursu S, Walker N, Willcockson M, Yan X, Ye Q, Powers JP.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):405-10. doi: 10.1016/j.bmcl.2010.10.129. Epub 2010 Oct 31.

PMID:
21093258
19.

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

Wang L, Wang GT, Wang X, Tong Y, Sullivan G, Park D, Leonard NM, Li Q, Cohen J, Gu WZ, Zhang H, Bauch JL, Jakob CG, Hutchins CW, Stoll VS, Marsh K, Rosenberg SH, Sham HL, Lin NH.

J Med Chem. 2004 Jan 29;47(3):612-26.

PMID:
14736242
20.

Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.

Mertens A, Zilch H, König B, Schäfer W, Poll T, Kampe W, Seidel H, Leser U, Leinert H.

J Med Chem. 1993 Aug 20;36(17):2526-35.

PMID:
7689109
Items per page

Supplemental Content

Write to the Help Desk